Radiopharm Theranostics Limited (ASX:RAD)
Australia · Delayed Price · Currency is AUD 0.0090
0.00 (0.00%)
Sep 11, 2026, 9:59 AM AEST
Radiopharm Theranostics Market Cap
Radiopharm Theranostics has a market cap or net worth of 39.04 million as of September 10, 2026. Its market cap has decreased by -43.08% in one year.
Market Cap
39.04M
Enterprise Value
32.54M
Revenue
13.50M
Ranking
n/a
PE Ratio
n/a
Stock Price
0.01
ChartMarket Cap Chart
Since November 25, 2021, Radiopharm Theranostics's market cap has decreased from 101.33M to 39.04M, a decrease of -61.48%. That is a compound annual growth rate of -18.04%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 10, 2026 | 39.04M | -55.94% |
| Dec 31, 2025 | 88.61M | 68.31% |
| Dec 31, 2024 | 52.65M | 91.43% |
| Dec 29, 2023 | 27.50M | -20.28% |
| Dec 30, 2022 | 34.50M | -65.53% |
| Dec 31, 2021 | 100.07M | -1.25% |
| Nov 25, 2021 | 101.33M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Prescient Therapeutics | 68.35M |
| Amplia Therapeutics | 66.73M |
| Botanix Pharmaceuticals | 57.47M |
| Neurizon Therapeutics | 48.06M |
| Nexsen | 36.04M |
| Imugene | 31.83M |
| NeuroScientific Biopharmaceuticals | 24.16M |
| Proteomics International Laboratories | 23.98M |